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Human hepatocellular cancers show decreased prostaglandin E1 binding
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Second Departments of 1Nuclear Medicine and 2Gastroenterology, University of Vienna, the Ludwig Boltzmann Institute for
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Summary Specific binding of 3H-PGE1 to plasma membranes prepared from normal human hepatic tissue in
the presence of Mg2+ reached saturation at concentrations greater than 50nm, and could be displaced in the
rank-order PGE1 >PGE2 >PGI2 >PGD2 >PGF2. at 4°C. Plasma membranes prepared from normal human
hepatic tissue showed a high-affinity 3H-PGE1-binding capacity of 51.3+19.2 fmolmg-1 plasma membrane
protein with an equilibrium dissociation constant of 3.8+ 1.9nm, and a low-affinity 3H-PGE1-binding capacity
of 104.2+17.3fmolmg-1 protein with an equilibrium dissociation constant of 13.9+2.7nm. Plasma mem-
branes prepared from hepatocellular cancer tissue revealed a single class of binding sites with an apparent
binding capacity of 38.4+ 17.3fmolmg-1 plasma membrane protein (P<0.05) and an equilibrium dissociation
constant of 12.1 +2.8 nm. Competition studies on plasma membranes prepared from hepatocellular cancer
tissue indicated no significant difference in the affinity of various prostaglandins to the receptor proteins as
compared to normal hepatic tissue. It is assumed that the decreased 3H-PGEl-binding capacity found in
human hepatocellular cancer tissue may reflect an alteration of the receptor protein content of the
hepatocytes during carcinogenesis.
Quite recently we found that prostaglandin I1 (PGI2) low
affinity binding sites observed in normal thyroids and in
benign thyroid adenomas were not demonstrable in thyroid
cancers. Furthermore, PGI2 high affinity binding sites were
significantly decreased in relation to the degree of differen-
tiation of the cancer (Virgolini et al., 1988a). Since various
other groups (Garrity et al., 1983; Nassar et al., 1985;
Okumura et al., 1985) investigated the properties of
prostaglandin-binding sites in rat hepatic tissue showing
important effects of prostaglandins via the mediation of
cAMP (Brass & Garrity, 1985; Sweat et al., 1983), and also
regulatory mechanisms at the receptor level (Garrity et al.,
1987), we investigated prostaglandin E1 (PGE,)-binding sites
in normal human hepatic tissue (Virgolini et al., 1988b).
Surprisingly we found an interspecies difference concerning
the number of binding sites between rat and human liver.
Since rat hepatomas have an increased PGE1-sensitive ade-
nylate cyclase activity and produce increased amounts of
cAMP (Allen et al., 1971; Bronstad et al., 1978, Bronstad &
Christofferson, 1981, Chayoth et al., 1973) we addressed the
question of whether the binding capacity for PGE1 would be
affected in human hepatocellular cancers.
Materials and methods
Materials
Normal human hepatic tissue samples were obtained from
six patients (4 female, 2 male, 37-67 years) undergoing
surgery for various cancers of the abdominal tract. Tissue
samples of hepatocellular cancers were obtained from six
other patients (4 female, 2 male, 43-61 years) undergoing
lobectomy. All the patients were without liver metastasis.
The tissue samples derived were immediately placed in 1 mM
NaHCO3-buffer (pH 7.5, 4°C) and controlled by routine
histology (Haematoxylin and Eosin stain).
K. Schillinger and T. Krais (Schering AG, Berlin, FRG)
kindly provided cold iloprost. 3H-PGE1 was obtained from
Amersham International, Buckinghamshire, UK (radio-
chemical purity 91.9%, specific activity 50.0MCimmol-1).
Unlabelled PGE1, PGE2, PGD2 and PGF2 L were obtained
from The Upjohn Company (Kalamazoo, Michigan, USA).
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Preparation of hepatic plasma membranes
Human hepatic plasma membranes were prepared (from
normal and cancer tissue) according to the method of
Neville (1968) as modified by Clarke et al. (1975). The
membranes floating on the top of the 42.4% sucrose were
removed with a wooden spatula and taken up in buffer
containing 50mM Tris-HCl (pH 7.8) and 5mM MgCl2, and
washed three times. Thereafter, the pellet was resuspended in
buffer at a protein concentration of about 100,ug 100p1-1
plasma membrane protein using the assay kit provided by
Bio-Rad (Commassic Brilliant Blue G-250, Richmond, CA,
USA). This membrane suspension was used within 30min
for the receptor-study.
Filtration assay of 3H-PGE1-binding experiments
Finally in the tubes a total assay volume of 200,ul was
incubated with the plasma membranes in a concentration of
about 100Mg 100g1-1 protein for 30min at 4°C. Stan-
dardised assay conditions were obtained from studies on
time and temperature dependency (Virgolini et al., 1988b).
Reproducibility was checked by measuring the count rates in
triplicate test tubes. The intra-assay variability.amounted to
4.9+0.9% and the interassay variability 6.3+1.9%.
Saturation experiments The plasma membranes were incu-
bated in 80Mt1 assay buffer with 20Ml of 3H-PGE1 in a
concentration range from 2.5 to 120nm in order to deter-
mine total binding. Twenty microlitres of the increasing
concentrations of 3H-PGE1 were incubated in 60M1 buffer in
the presence of 20M1 of 500 Mm unlabelled PGE1 to deter-
mine non-specific binding. The difference between both is
referred to as specific binding.
Displacement studies Protein was incubated with 15nm of
3H-PGE1 to determine total binding for these experiments
and with concentrations from 50pM to 500 Mm of unlabelled
PGE1. In order to study competition of binding to the
PGEl-receptor, experiments with the unlabelled prostanoids
PGE2, iloprost (chemically stable PGI2-analogue) PGF2a and
PGD2 were similarly tested.
Filtration After an incubation time of 30min at 4°C the
reaction mixture was diluted rapidly with 3ml of 4°C buffer
and the entire mixture immediately poured onto a Whatman
GF/C filter (Maidstone, UK), which was positioned on a
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vacuum system (Millipore, Harrow, UK). The tubes werc
then rinsed once with 5ml buffer and each filter was then
washed successively with two 5ml portions of buffer. After
completion of filtration and washing (lasting for less than
10s) the filters were dried at room temperature. Thercafter
they were transferred into scintillation vials (Packard,
Downers Grove, USA) and taken up into 10ml scintillation
fluid (Pico-Fluor TM30, Packard, Downers Grove, USA).
The radioactivity in the samples was counted for 5min in a
liquid scintillation counter (LKB Wallace, 1215 Rackbeta,
Turku, Finland).
Statistical analysis of the experiments
Calculation in terms of Scatchard analysis was done by a
computer program defining two independent binding sites
(kindly provided by M. Freissmuth, Department of Pharma-
cology, University of Vienna). Significance was tested by the
Student's t test for paired data. Values arc given as mean
+s.d.
Results
Saturationi of PGE -hinding to plasma membranes prepared
fronm normnial hulman hepatic tissule
The specific binding of 3H-PGEI to hepatic plasma mem-
branes amounted to 85+5% in the presence of 500piM
unlabelled PGE1. Saturation was reached at a 3H-PGE1
concentration of more than 50nM. The Scatchard analysis
on 3H-PGE1 saturation data (Figure 1) was curved, indicat-
ing two independent binding sites. The high affinity binding
sites saturated at 51.3+19.2 fmolmg -I plasma membrane
protein and showed a Kd of 3.8 + 1.9 nM. The low affinity
sites saturated at 104.2 + 17.4 fmol mg l protein and showed
a Kd of 13.9+2.7nM.
Saturation of PGEI-binding to plasma1 membranes prepared
froml humnan hepatocellular canceir.s
The specific binding of 3H-PGE1 to plasma membranes
prepared from hepatocellular cancer tissue amounted to
75+10% in the presence of 500p1M unlabelled PGEI. Satur-
ation was reached at 3H-PGE1 concentration of more than
20nM. The Scatchard analysis on 3H-PGE saturation data
(Figure 2) was clearly linear and revealed a single class of
binding sites saturating at 38.4 + 17.3 fmol mg- 1 plasma mem-
brane protein and showed a K1 of 12.1 +2.8nM.
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Figure 2 Saturation of the specific bindinig of 3H-PGE, to
hcpatocellular cancers (n=6) in the presence of Mg2+ at 4 C.
Non-specific binding (500pIM) was subtracted from total bindinig
to determine the specific binding (75+ 10%). No further increase
in binding was observed in ligand coincentrations of more than
60nM). Inset: Scatchard analysis.
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Figure 3 Displacement of specific bindinig of 30nm1 3H-PGE, to
normlal hepatic plasma membranes (filled columinis, =6) and
plasimia membraines of hepatocellular cancers (opCIe coluimins.
n =6) by various prostanoids. IC concentrationi clausing half
milaxilmal inhibitionl.
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Figure 1 Saturation of the specific binding of 3H-PGE, to
normal human liver plasma membranes (n =6) in the presence of
Mg2 at 4 C. Non-specific binding (500 ItM) was subtracted from
total binding to determine the specific binding (85+5%). Inset:
Scatchard analysis.
PGF,, PGE2, iloprost, PGF2, and PGD, caused a dose-
dependent inhibition of 3H-PGEI-binding to normal humian
hepatic plasma membranes (Figure 3). The rank-order of
potency was indicated by PGE, >PGE2>
PGI2 >PGD2>PGF21-
-iDisplacement of 3H-PGEl-binding to plasma membranes
preparedfrom human hepatocellular cancers
PGE1, PGE2, iloprost, PGF20 and PGD2 caused a dose-
dependent inhibition of 3H-PGE1-binding to plasma mem-
branes of hepatocellular hepatoma (Figure 3). The rank-
order of potency was indicated by PGE1IPGE2>
PGI2 >PGD2>PGF2V. There was no significant difference
between normal hepatic tissue and hepatocellular cancer
tissue.
Discussion
The major objective of the present study has been the
evaluation of the in vitro binding of 3H-PGE1 to hepato-
cellular cancer tissue compared to normal hepatic tissue.
Whereas the specific binding of 3H-PGE1 to normal hepatic
plasma membranes could be subdivided in high affinity
binding sites (Kd=3.8+1.9nM) with a low capacity and in
low affinity binding sites (Kd=13.9+2.9nM), presenting the
majority of the receptor population with a higher capacity,
the specific binding of 3H-PGE1 to plasma membranes
prepared from hepatocellular cancer tissue indicated a single
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class of lower affinity binding sites (Kd= 12.1 + 2.8 nM) exhi-
biting a significantly lower capacity than at normal hepatic
plasma membranes (P<0.005).
Although we could only study six hepatocellular cancers,
the loss of the higher affinity 3H-PGE1-binding sites seems
to reflect a common event for the malignant hepatoma. A
similar alteration of the binding capacity was recently
obtained for thyroid cancers with respect to the 3H-PGE1-
binding sites (Virgolini et al., 1988a). It is of interest that
some authors reported on a more increased PGE1-sensitive
adenylate cyclase activity in rat hepatomas (Allen et al.,
1971; Bronstad & Christofferson, 1981; Chayoth et al.,
1973). Apart from an interspecies difference in the binding
capacities of rat and human hepatic plasma membranes
(Virgolini et al., 1988b) this demonstration might also impli-
cate a down-regulation mechanism at the prostaglandin
receptor level. However, the role of prostaglandins in cancer
is not clear at all. The role of the arachidonic acid metabo-
lites in physiological and pathophysiological states is cur-
rently under intensive investigation and the biological action
of these compounds has been implicated in many key
regulatory processes. Therefore, it is not unreasonable to
predict that these compounds may have a central role in the
initiation and regulation of the spectrum of diseases which
we functionally call cancer.
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